2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Alexander Drilon, MD, discusses prior therapy and performance status outcomes for larotrectinib in patients with non-CNS TRK fusion cancer that were presented at the European Society of Medical Oncology 2021 annual meeting.
OncLive® Rapid Readout from European Society for Medical Oncology 2021: Results for Larotrectinib in Non-CNS TRK Fusion Cancer Patients: Outcomes by Prior Therapy and Performance Status
Alexander Drilon, MD, discusses data from the following presentation: “Larotrectinib in Non-CNS TRK Fusion Cancer Patients: Outcomes by Prior Therapy and Performance Status.” (ESMO Drilon Abstract 534P)
Segment Body Content: